Coronary Physiology in STEMI patients today: Why? When? How?
Published: 08 April 2022
-
Views:
1123 -
Likes:
7
-
Views:
1123 -
Likes:
7
-
Up Next
-
11m 8sPart 1 | Session 3 Practical Solutions
-
10m 37sPart 1 | Session 4 Discussion and Closing Remarks
-
10m 56sPart 2 | Session 1 Welcome and Introduction
-
22m 33sPart 2 | Session 2 Daily Practice Experience
-
6m 53sPart 2 | Session 3 Future Perspectives
-
13m 8sPart 2 | Session 4 Discussion and Closing Remarks
-
13m 2sPart 1 | Session 1 Introduction and Clinical Evidence Ziad A Ali, Joost Daemen, Zsolt Piroth
Overview
Physiology in STEMI patients is a controversial hot topic in interventional cardiology: it has been first demonstrated to enhance the benefits of full revascularization vs PCI only in the culprit lesion; then its effectiveness has been mitigated by clinical outcomes not showing any differences versus angiography-guided complete revascularization.
Join a panel of international expert in the discussion about a topic that is still controversial and may impact a large number of STEMI patients undergoing PCI.
Clinical evidence and cases from the real world will be the two key subjects debated during the breakout session at TIO 2022.
Key Learning Objectives
- To understand the current position of Key Opinion Leaders on physiology in STEMI patients
- To actively participate to the debate over the options offered in the cathlab to support physiology guided complete revascularization in STEMI patients
- To review the literature and defining the key clinical settings where physiology should play a role in the decision making
Target Audience
- Interventional Cardiologists
- Surgeons with an interest in transcatheter treatment strategies for coronary and structural heart disease
- Interventional Cardiology Nurses
More from this programme
Part 1
Coronary Physiology in STEMI Patients Today: Why? When? How?
Part 2
Coronary Physiology in Diffuse Disease
Faculty Biographies
Joost Daemen
Interventional Cardiologist
Dr Joost Daemen is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center. He is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.